- Home
- News & Events
- In the News
In the News
ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
-
Engineering CAR T-cell sharpshooters
In this article, ICON's Brian Huber explains why and discusses the prospects for the next-generation of CAR T-cell therapies engineered to be more adaptable, precise and controlled.
-
ICON announces pricing of USD 2 billion notes
Announced the pricing of a USD 2 billion SEC-registered bond offering, consisting of $750,000,000 5.809% Senior Secured Notes due 2027, $750,000,000 5.849% Senior Secured Notes due 2029 and $500,000,000 6.000% Senior Secured Notes due 2034 (collectively, the “Notes”).
-
Advancing Research and Development of Multi-indication and Combination Therapies for Obesity
In this article, ICON's Jack Martin explores obesity’s pathophysiology is highly complex and characterised by a multitude of interrelated factors. Explore the impact of comorbidities on obesity therapeutic development including strategic and innovative approaches to therapeutic development and clinical trials design.
-
Enabling evidence-based study endpoint selection
In this article from Applied Clinical Trials, Marcelo Alves Favaro, Associate Outcomes Researcher, MAPI Research Trust, Caprice Sassano, Research Lead - Applied Sciences at HumanFirst and Roya Sherafat, Scientific Director, MAPI Research Trust explore how digital health technologies and patient-centred assessments can be evaluated side-by-side to rapidly select the right tool and the right measures, ultimately reducing patient burden.
-
Overcoming challenges in obesity-related clinical trials
Recent advancements in obesity treatments have spotlighted the field for healthcare providers and developers. In this article from Drug Discovery World, ICON experts share insights on the clinical trials landscape for obesity and why patient centricity is key to overcoming common challenges in the sector.
-
Advancing clinical research through effective data delivery
In this article from The Scientist, Rose Kidd, President of Global Operations Delivery, explains how clinical researchers ensure impeccable data collection and delivery in increasingly complex trials.
-
Biotech sector survey: From investment confidence to strategic collaborations
In this article from International Biopharmaceutical Industry, Chris Smyth, President of ICON Biotech outlines the findings of the recent ICON biotech sector survey, and explores the role of partnerships and the increasing trend of pharma collaboration, even at the pre-clinical stage.
-
Clinical supply CDMOs rejig service models
In this article from Contract Pharma, Kelly Corkey, Director, Clinical Supplies Management, IRT provides commentary on how clinical supply services are changing as next-gen biotherapeutics and direct-to-patient trials transform the clinical research arena, disrupting the traditional supply models.
-
Data integration frameworks key for embracing big data’s potential
Rick Rosenthal and Paula Fullman of Symphony Health, an ICON plc company, explain how to navigate the complexities and challenges of the evolving digital landscape of healthcare data in this article from PharmaTimes.
-
Winners recognised amid record entries for the PwC Business Post Sustainable Business Awards
This article in the Business Post lists ICON as the winner of the Social and Equality Business of the Year Award category of the 2024 PwC Business Post Sustainable Business Awards.